Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-641: Pembrolizumab plus enzalutamide in metastatic castration-resistant prostate cancer
2022-500785-10-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab plus enzalutamide with Placebo plus enzalutamide (2 arms). Primary endpoints: Overall Survival and Radiographic Progression-free Survival. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-500785-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500785-10-00.